{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:26:10Z","timestamp":1790727970069,"version":"4.1.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006451","name":"Hospices Civils de Lyon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006451","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Mycology Case Reports"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.mmcr.2022.06.003","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T02:11:12Z","timestamp":1655086272000},"page":"19-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Nivolumab and interferon-\u03b3 rescue therapy to control mixed mould and bacterial superinfection after necrotizing fasciitis and septic shock"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9372-1533","authenticated-orcid":false,"given":"Anne-Claire","family":"Lukaszewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0462-4235","authenticated-orcid":false,"given":"Fabienne","family":"Venet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Boibieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Lherm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Devigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Monneret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.mmcr.2022.06.003_bib1","doi-asserted-by":"crossref","first-page":"ofab256","DOI":"10.1093\/ofid\/ofab256","article-title":"IL-7 Immunotherapy in a nonimmunocompromised patient with intractable fungal wound sepsis","volume":"8","author":"Turnbull","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.mmcr.2022.06.003_bib2","article-title":"Immune profiling demonstrates a common immune signature of delayed acquired immunodeficiency in patients with various etiologies of severe injury","volume":"10","author":"Venet","year":"2021","journal-title":"Crit. Care Med."},{"issue":"12","key":"10.1016\/j.mmcr.2022.06.003_bib3","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nri3552","article-title":"Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy","volume":"13","author":"Hotchkiss","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.mmcr.2022.06.003_bib4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/23744235.2019.1597983","article-title":"Scarce evidence of efficacy of hyperbaric oxygen therapy in necrotizing soft tissue infection: a systematic review","volume":"51","author":"Thrane","year":"2019","journal-title":"Inf. Disp."},{"issue":"1","key":"10.1016\/j.mmcr.2022.06.003_bib5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1473-3099(16)30541-2","article-title":"Nivolumab plus interferon-\u03b3 in the treatment of intractable mucormycosis","volume":"17","author":"Grimaldi","year":"2017","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.mmcr.2022.06.003_bib6","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1186\/s12879-019-4526-x","article-title":"Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series","volume":"19","author":"Payen","year":"2019","journal-title":"BMC Infect. Dis."},{"issue":"5","key":"10.1016\/j.mmcr.2022.06.003_bib7","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/jof7050330","article-title":"Emerging invasive fungal infections in critically ill patients: incidence, outcomes and prognosis factors, a case-control study","volume":"7","author":"Larcher","year":"2021","journal-title":"J Fungi (Basel)"},{"issue":"suppl_1","key":"10.1016\/j.mmcr.2022.06.003_bib8","doi-asserted-by":"crossref","first-page":"i39","DOI":"10.1093\/jac\/dkx032","article-title":"Invasive mould infections in the ICU setting: complexities and solutions","volume":"72","author":"Bassetti","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"issue":"10","key":"10.1016\/j.mmcr.2022.06.003_bib9","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s00134-019-05704-z","article-title":"Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab","volume":"45","author":"Hotchkiss","year":"2019","journal-title":"Intensive Care Med."},{"issue":"6","key":"10.1016\/j.mmcr.2022.06.003_bib10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/SHK.0000000000001443","article-title":"Pharmacokinetics, pharmacodynamics, and safety of nivolumab in patients with sepsis-induced immunosuppression: a multicenter, open-label phase 1\/2 study","volume":"53","author":"Watanabe","year":"2020","journal-title":"Shock"},{"issue":"12","key":"10.1016\/j.mmcr.2022.06.003_bib11","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect. Dis."}],"container-title":["Medical Mycology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211753922000252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211753922000252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T18:03:24Z","timestamp":1761933804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211753922000252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":11,"alternative-id":["S2211753922000252"],"URL":"https:\/\/doi.org\/10.1016\/j.mmcr.2022.06.003","relation":{},"ISSN":["2211-7539"],"issn-type":[{"value":"2211-7539","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nivolumab and interferon-\u03b3 rescue therapy to control mixed mould and bacterial superinfection after necrotizing fasciitis and septic shock","name":"articletitle","label":"Article Title"},{"value":"Medical Mycology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mmcr.2022.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of International Society for Human and Animal Mycology.","name":"copyright","label":"Copyright"}]}}